Publications by authors named "Janelle M Meyer"
Article Synopsis
- * It involved 20 patients, with some receiving sorafenib alongside chemoradiotherapy, and others just chemoradiotherapy, using MRI scans at various treatment points to assess tumor response.
- * The research found that specific DCE-MRI parameters, like the rate constant (K), are stronger predictors of treatment response and correlation with tumor necrosis than standard size measurements, demonstrating their potential for improved early evaluation.
Purpose: We conducted a phase I trial of the addition of sorafenib to a chemoradiotherapy regimen in patients with high-risk (intermediate/high grade, >5 cm) extremity soft tissue sarcoma undergoing limb salvage surgery. We conducted a correlative study of quantitative dynamic contrast-enhanced MRI (DCE-MRI) to assess response to treatment.
Experimental Design: Patients were treated at increasing dose levels of sorafenib (200 mg daily, 400 mg daily, 400 mg twice daily) initiated 14 days before three preoperative and three postoperative cycles of epirubicin/ifosfamide.